Application of benvitimod on psoriasis: A systematic review and meta-analysis of randomized controlled trials. A systematic review of benvitimod on psoriasis - 22/10/21
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Summary |
Background |
We conducted this systematic review to clarify the efficacy and safety of benvitimod on psoriasis.
Methods |
We searched the databases of PubMed, China National Knowledge infrastructure, Cochrane Library, Embase, Web of science to identify randomized controlled trials (RCTs) of benvitimod on psoriasis up to April 2021.
Results |
Five RCTs of benvitimod on psoriasis were included. A total of 1237 patients were included. 0.5% or 1.0% benvitimod was applied topically once or twice a day. More patients in benvitimod group achieved PASI 90, PASI 75, PASI 50 and BSA reduction than placebo at Week 12. More patients in benvitimod group achieved PGA 0 or 1 than placebo since Week 6. There were no statistical significances in efficacies of benvitimod at different concentrations and frequencies.
Conclusions |
Benvitimod was effective and safe for psoriasis. More RCTs with high qualities are needed to further verify the current conclusion.
Le texte complet de cet article est disponible en PDF.Keywords : Benvitimod, Tapinarof, Aryl hydrocarbon receptor (AhR), Psoriasis
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?